Industry Payments & KOL Market Paper
CMS Open Payments (Sunshine Act) general payments · companies, payment types, states, specialties and top recipients
Who pays clinicians and how: national company ranking, speaking/consulting/meals/travel mix, state totals, recipient types, most-promoted products and the most-paid individual speakers and consultants, from the latest CMS Open Payments program year.
Built for Pharma and device commercial teams, medical affairs, compliance officers and healthcare investors.
What's inside the full paper
- Executive summary
- Payment types
- Top paying companies
- Payments by recipient state
- Recipient types
- Products most linked to payments
- Most-paid individual recipients (KOL candidates)
- Methods and limits
Free preview
Executive summary
Prepared 2026-11-20 from CMS Open Payments 2025 general payments (national totals stored 2026-11-11). Drug and device manufacturers and group purchasing organizations reported $3,923,363,992 in 16,131,363 general payments to U.S. clinicians and teaching hospitals.
1,758+ reporting companies appear; the top five account for 27.8% of the total. The largest payment types are Royalty / license ($1,203,443,513), Speaker / faculty ($751,881,628), Consulting ($648,985,308).
Open Payments is company-reported. A payment is not evidence of wrongdoing, influence or prescribing; amounts are separate from Medicare billing and are never added to claims figures. Research payments and ownership interests are separate CMS files and are not included here.
Payment types
Nature of payment as reported to CMS.
| Type | Payments | Amount | Share |
|---|---|---|---|
| Royalty / license | 15,496 | $1,203,443,513 | 30.7% |
| Speaker / faculty | 249,154 | $751,881,628 | 19.2% |
| Consulting | 205,079 | $648,985,308 | 16.5% |
13 more rows in the full paper
Top paying companies
Ranked by total general payments; company names as submitted to CMS (one parent may report under several names).
| Company | Payments | Amount | Share |
|---|---|---|---|
| BioNTech SE | 147 | $536,410,036 | 13.7% |
| ABBVIE INC. | 1,682,658 | $201,690,737 | 5.1% |
| Stryker Corporation | 212,944 | $133,465,720 | 3.4% |
47 more rows in the full paper
Statistical results are review leads, not findings of fraud. See our sources.
